#End Users in US Acute Myeloid Leukemia Market | Explore Tumblr Posts and Blogs

kenresearch1 · 10 months

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes

itssashasharma · 3 years

Text

Global Hemato Oncology Testing Market worth USD 4.0 billion by 2024 : Increasing Incidence of Hematologic Cancer

The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research.

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study. According to the new market research report “Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%. Browse in-depth TOC on “Hemato Oncology Testing Market“ 77 – Tables 29 – Figures 116 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays. The services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market in 2018. Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population. Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment Based on end-user, the Hemato Oncology Testing Market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests. North America accounted for the largest share of the Hemato Oncology Testing Market in 2018 North America accounted for the largest share of the Hemato Oncology Testing Market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period. Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 Some of the leading players in the Hemato Oncology Testing Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Browse Related Reports: Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laborato https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical

Companies, Reference Lab) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp

0 notes

industryarcmarketresearch · 3 years

Text

Acute Myeloid Leukemia Therapeutics Market Size Forecast to Reach $18.3 Billion by 2026

Acute Myeloid Leukemia Therapeutics market size is forecast to reach $18.3 billion by 2026, growing at a CAGR of 7.2% during the forecast period 2021-2026. Leukemia affects the white blood cells and bone marrow. It is characterized by the rapid increase of abnormal blood cells growth that reduces the numbers of fully modified blood cells which leads to the typical symptoms of anemia, bleeding, and high risk of infection. Leukemia can grow along the lymphoid stem cell lines or myeloid depending upon the epigenetic and genetic mutations of the pluripotent stem cells. The leukemia that occurs along the myeloid are known as acute myeloid leukemia and it is a serious condition that is suffered by adult people. Various types of treatments that includes cytarabine, mitoxantrone, tyrosine kinase inhibitors, and imatinib among others are used for acute myeloid leukemia therapeutics. Increasing prevalence of acute myeloid leukemia and increased drug approval rate for acute myeloid leukemia are the major factors driving the growth of the market. Large number of treatment options available for treatment of acute myeloid leukemia and increasing funding for cancer research & development of new therapies is set to further enhance the overall market development of the Acute Myeloid Leukemia Therapeutics Market for the period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Segment Analysis – By Treatment Type

Cytarabine held the largest share in the Acute Myeloid Leukemia Therapeutics Market in 2020 and is estimated to grow at a CAGR 7.7% during the forecast period 2021-2026. Cytarabine is used for the treatment of different types of leukemia such as acute and chronic myeloid leukemia among others. Owing to its effectiveness in the treatment of acute myeloid leukemia, it is being widely used during chemotherapy process. Macmillan Cancer Support, an organization that is working for cancer have stated that cytarabine is more effective for the treatment of acute myeloid treatment. Chemotherapy kills the cancer cells that metastasized across the different parts of the body. Cytarabine is estimated to register the highest CAGR over the period 2021-2026.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=507054

Report Price: $ 5900 (Single User License)

Acute Myeloid Leukemia Therapeutics Market Segment Analysis – By End User

Hospitals held the largest share in the Acute Myeloid Leukemia Therapeutics Market in 2020 and is estimated to grow at a CAGR 7.4% during the forecast period 2021-2026. Chemotherapy is majorly used for consolidation therapy of acute myeloid leukemia. In hospitals, younger adults are given mainly four rounds of high or immediate dose of cytarabine at monthly intervals and several different regimes are used for older patients. Chemotherapy is usually given in the hospital and recovery time can be spent at home. Hospitals are estimated to register the highest CAGR over the forecast period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Segment Analysis – By Geography

North America dominated the Acute Myeloid Leukemia Therapeutics Market with a major share of 38.3% in 2020. This is attributed to the increasing research in the field of regenerative medicine for treatment of acute myeloid leukemia. Growing awareness on personalized medicine, high incidences of leukemia, and huge investment in the development of pipeline drug is also increasing the growth of the market in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the rising investment and increasing cancer awareness. Improving healthcare infrastructure and increasing inclination towards targeted therapies is also increasing the growth of the market in this region.

Acute Myeloid Leukemia Therapeutics Market Drivers

Increasing prevalence of acute myeloid leukemia

Increasing prevalence of acute myeloid leukemia is increasing the growth of the Acute Myeloid Leukemia Therapeutics Market. Acute Myeloid Leukemia begins in the bone marrow and quickly moves into the blood. It can also spread to other parts of the body such as liver, spleen, testicles, and central nervous system. It develops from those cells that turns into white blood cells. Radiation therapy or surgery in cancer patients removes the cancer cells in a specific area but chemotherapy works through the body and gives a better result. According to the estimation done by The American Cancer Society, around 61,780 new cases and 22,840 deaths from leukemia has been reported in 2019.Thus, increasing the growth of the Acute Myeloid Leukemia Therapeutics Market during the forecast period 2021-2026.

Increasing Cancer Awareness

Increasing cancer awareness is increasing the growth of the Acute Myeloid Leukemia Therapeutics Market. This is attributed to the fact that according to the World Health Organization, one third of all cancers are preventable and this can be done by taking a free cancer risk test that identifies the behaviors that can lead to cancer and ways to reduce the risk. As of 2019, 16.9 million cancer survivors are there in U.S. and number of cancer survivors are set to increase to 22.2 million by 2030.Thus, increasing the growth of the Acute Myeloid Leukemia Therapeutics Market during the forecast period 2021-2026.

Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=507054

Acute Myeloid Leukemia Therapeutics Market Challenges

High Cost of the Therapeutics Process and its Safety Concerns

Some of the factors that are set to impede the growth of the Acute Myeloid Leukemia Therapeutics Market are high cost of the therapeutics process and its safety concerns. Lack of targeted therapies in current acute myeloid leukemia therapeutics and difficult approval process for drugs is also set to hinder the growth of the market during the forecast period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Landscape

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Acute Myeloid Leukemia Therapeutics Market. In 2020, the Acute Myeloid Leukemia Therapeutics Market share is consolidated by the top ten players present in the market. Acute Myeloid Leukemia Therapeutics Market, top 10 companies are Pfizer Inc., Eisai Inc., Cephalon Inc., Celegene Corporation, Bristol,, Novartis AG, Genzyme Corporation, Eli Lily & Company, Amgen, and Gilead Sciences among others.

Key Takeaways

North America dominated the Acute Myeloid Leukemia Therapeutics Market in 2020 owing to the increasing research in field of regenerative medicine for treatment of acute myeloid leukemia and growing awareness on personalised medicines. The Acute Myeloid Leukemia Therapeutics Market scope for different regions will be provided in the final report.

Increasing advantages of biopharmaceuticals over conventional medicines and strong biopharmaceuticals pipeline are likely to aid the market growth of the Acute Myeloid Leukemia Therapeutics Market report.

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Acute Myeloid Leukemia Therapeutics Market report.

High cost of the therapeutics process and its safety concerns is poised to create hurdles for the Acute Myeloid Leukemia Therapeutics Market.

Related Reports:

A. Acute Lymphoblastic Leukemia Therapeutics Market

https://www.industryarc.com/Research/Acute-Lymphoblastic-Leukemia-Therapeutics-Market-Research-509670

B. B-cell Chronic Lymphocytic Leukemia Market

https://www.industryarc.com/Research/B-cell-Chronic-Lymphocytic-Leukemia-Market-Research-509962

For more Lifesciences and Healthcare Market reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

#AcuteMyeloidLeukemiaTherapeuticsMarket #AcuteMyeloidLeukemiaTherapeuticsMarketshare #AcuteMyeloidLeukemiaTherapeuticsMarketsize

0 notes

kennethresearch · 3 years

Text

Global Asparaginase Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Global Asparaginase Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Asparaginase Market products.

Get Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

It is also anticipated to grow on account of the growing demand for chemicals from the end users, backed by the increasing consumption of chemicals across different industries and the rising need for advanced chemicals. In India, the production of major chemicals and petrochemicals during the period 2020-2021 was close to 12000 thousand MT. Additionally, between the period 2015-16 and 2019-20, the production of the chemicals and petrochemicals in the nation grew at a CAGR of close to 6%.

Global Asparaginase Market is valued approximately at USD XXX million in 2018 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2019-2026. Asparaginase is an enzyme which catalzes the hydrolysis of l-asparagine to l-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. These are used widely in Healthcare industry and Food manufacturing industry as a medication. It is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. As Asparaginase was approved for medical use in the United States in 1978. It is also on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Asparaginase is used in the food manufacturing to reduce the formation of acrylamide. Acrylamide is a carcinogen in the starch containing food products such as biscuits and snacks. Thus, the rapidly growing healthcare and food manufacturing industry increase the demand for Asparaginase during the forecast period. As the Food and drinks market in Europe contributed to be the largest manufacturing sector in 2017 with a turnover of USD 1222 billion. The same sector invested USD 3.12 billion in research & development in 2017 which shows a positive sign in the market growth. Further, the rising investments of the market players for the research and development and production of Asparaginase according to the regulatory specification due to the rise in demand further fuels the market growth. However, the side effects of Asparaginase on human body such as mild bone marrow suppression, pancreatitis, anticoagulant factor resulting in stroke and bleeding hinders the market growth.

The regional analysis of global Asparaginase market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the dominant pharmaceutical industry in the region which is the major industry which uses Asparaginase enzyme. Further rising cases of Leukemia in the region propel the market growth. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing population along with increasing disposable income coupled with growing food manufacturing industry would create lucrative growth prospects for the Asparaginase market across Asia-Pacific region.

Major market player included in this report are: Jazz Pharmaceuticals Plc Shire Plc Medac GmbH Kyowa Hakko Kirin Co., Ltd. Qianhong Bio-pharma Taj Pharmaceuticals Mingxing Pharma Exova SL Pharma Inc United Biotech Pvt. Ltd. Novus Biologicals The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Escherichia Coli Erwinia Chrysanthemi Pegylated By Application: Healthcare Food Industry Others By Region: North America U.S. Canada Europe UK Germany Asia Pacific China India Japan Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017 Base year – 2018 Forecast period – 2019 to 2026

Target Audience of the Global Asparaginase Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investor

Download Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys & Opportunity Outlook

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Kenneth Research

Email : [email protected]

Phone: +1 313 462 0609

0 notes

healtcare · 3 years

Text

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

#Haematology #Flow Cytometry #Haematology and Flow Cytometry

0 notes

rdagade · 3 years

Text

Global Haematology and Flow Cytometry Market

is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Global Haematology and Flow Cytometry Market Dynamics:

Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives.

ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.

To know about the Research Methodology :-

Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-haematology-and-flow-cytometry-market/98749/

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [email protected]

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

#Global Haematology and Flow Cytometry Market

0 notes

newsbulletin · 3 years

Text

Global Platelet Aggregation Devices Market Trends, Industry Report 2027

New York, NY 14 May 2021: The global platelet aggregation devices market size is expected to reach USD 1,556.8 million by 2027 according to a new study by Polaris Market Research. The report “Platelet Aggregation Devices Market Share, Size, Trends, Industry Analysis Report, By Product (Systems, Reagents, Consumables and Accessories); By Application (Research Applications, Clinical Applications, Others); By End Use (Standalone Hospitals, Diagnostic Laboratories, Research and Academic Institutes, Blood Banks, and Other End Users); By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Platelet aggregation is the biological process where the platelet cells are employed in a process to prevent bleeding through vaso-constriction for rapid clot formation. The whole process is mediated via platelet aggregating factor (PAF). The quantitative and qualitative defects of platelets lead to increased bleeding. The high reactivity of platelets in the patients having anti-platelet therapy results in thromboembolic complications.

Platelet function related disorders can be either inherited or acquired. The inherited platelet function disorders include Von Willebrand disease, Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, Storage pool disease. The acquired platelet dysfunction may be caused by chronic conditions such as kidney failure (uremia), Myelodysplastic syndrome (MDS), Leukemias (chronic myeloid leukemia or CML; acute myeloid leukemia or AML).

Some acquired platelet disorders are temporary because of the decreased function of platelets due to anti-platelet medications, non-steroidal anti-inflammatory drugs (NSAIDs), tricyclic antidepressants, antihistamines and some antibiotics. The platelet function testing is transitioned from diagnostics for heritable diseases to a functional one for platelet functional therapies. The rapid usage of anti-platelet therapy, mainly dual anti-platelet therapy has changed the focus of platelet function testing from diagnostics to therapeutics.

Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample

The market is driven by few notable factors such as the recent surge in infectious diseases (COVID-19) requiring rapid serological tests, innovations in platelet aggregation mechanisms, systems and consumables, and worldwide rise in chronic ailments. Specialized tests based on platelet aggregation include light transmission platelet aggregometry on platelet-rich plasma (LTA), impedance whole blood aggregometry (WBA), Lumi-aggregometry and flow cytometry.

Automated haematology analyzers can be used to obtain platelet counts over a wide range of values using optical counting methods like light scatter or fluorescence. Screening tests such as prothrombin time (PT) or activated partial thromboplastin time (aPTT) are more standardized and fully automated.

Number of reagents are available in the market to carry out the platelet function tests. These reagents include collagen, thrombin, ADP, vasopressin, epinephrine and ristocetin. Collagen, ADP were used in routine platelet aggregation studies for the evaluation of qualitative platelet function disorders.

Market participants such as F. Hoffmann La-Roche Ltd., Drucker Diagnostics, Haemonetics Corporation, Sysmex Corporation, Siemens Healthineers, Chrono-log Corporation, Instrumentation Laboratory, Accriva Diagnostics, Matis Medical, Helena Laboratories Corporation, Sienco, Inc., Bio/Data Corporation, Tem Group, WerfenLife, S.A., Laboratory Corporation of America Holdings, Sentinel CH. S.p.A., and Aggredyne, Inc. are some of the key players operating in the concerned market.

To get Incredible Discounts on this Premium Report, Click At: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-discount-pricing

Polaris Market research has segmented the vascular access devices market report on the basis of product, application, end-use and region

Platelet Aggregation Devices Type Outlook (Revenue – USD Million, 2016 – 2027)

Systems

Reagents

Consumables and Accessories

Platelet Aggregation Devices Application Outlook (Revenue – USD Million, 2016 – 2027)

Research Applications

Clinical Applications

Others

Platelet Aggregation Devices End-Use Outlook (Revenue – USD Million, 2016 – 2027)

Standalone Hospitals

Diagnostic Laboratories

Research and Academic Institutes

Blood Banks

Other End Users

Have Any Query or Specific Requirement? Request for customization: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-customization

About Polaris Market Research

Polaris Market Research

Phone: 1–646–568–9980

Email: [email protected]

Web: http://www.polarismarketresearch.com

#Platelet Aggregation Devices market Platelet Aggregation Devices Insight Platelet Aggregation Devices Growth Platelet Aggregation Devices si

0 notes

cool-cillian-murphy · 3 years

Text

Asparaginase Market - A Story of Very Rapid Development

Latest released the research study on Global Asparaginase Market, offers a detailed overview of the factors influencing the global business scope. Asparaginase Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Asparaginase. The study covers emerging player’s data, including: competitive situation, sales, revenue and global market share of top manufacturers are Porton Biopharma (England), Jazz Pharmaceuticals (Ireland),Takeda (Japan),ERYTECH Pharma (France),Qianhong Bio-pharma (China),Mingxing Pharma (China),Medac GmbH (Germany),Kyowa Hakko Kirin (Japan),Alize Pharma (France),Guangzhou Baiyuan Shanmingxing Pharmaceutical (China),.

Free Sample Report + All Related Graphs & Charts @ : https://www.advancemarketanalytics.com/sample-report/6507-global-and-united-states-asparaginase-market Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Global Asparaginase Market various segments and emerging territory.

Asparaginase Market Overview Asparaginase is a microbial product derived from Escherichia coli or from Erwinia chrysanthemi. Asparaginase is a white crystalline powder which contains the enzyme L-asparagine amidohydrolase derived from Escherichia. L-asparaginase has been reported to interface with the interpretation of thyroid function tests. It contains fungi from extreme environments which lead to the development of new chemotherapeutic treatment methods that have fewer side- effects than others. The general trade names for l-asparaginase in the United States are Elspar and Kidrolase. Market Drivers Growing Number of Cancer Patients in the United States

Increase Number Patients with Acute Lymphocytic Leukemia

Market Trend High Adoption to Treat Childhood Cancer Treatments

Increase Demand for Human Brain Function and In Ammonia Physiology

Restraints Increasing Cost of the Asparaginase Drugs Is Hamper the Growth of the Market Challenges Increasing Number of Side Effects Such As Fever, Vomits, Allergic Reaction and Others The Global Asparaginase Market segments and Market Data Break Down are illuminated below: by Type (E. Coli Asparaginase, Erwinia Asparaginase, Pegylated Asparaginase), Application (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia), Distribution Channel (Pharmacies, Convenience Store, Online Sales, Other) Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc. Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/6507-global-and-united-states-asparaginase-market Strategic Points Covered in Table of Content of Global Asparaginase Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Asparaginase market

Chapter 2: Exclusive Summary – the basic information of the Asparaginase Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Asparaginase

Chapter 4: Presenting the Asparaginase Market Factor Analysis, Post COVID Impact Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Asparaginase market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2026)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source Finally, Asparaginase Market is a valuable source of guidance for individuals and companies in their decision framework. Data Sources & Methodology The primary sources involves the industry experts from the Global Asparaginase Market including the management organizations, processing organizations, analytics service providers of the industry’s value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects. In the extensive primary research process undertaken for this study, the primary sources – Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Company's Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age. For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/6507-global-and-united-states-asparaginase-market What benefits does AMA research studies provides?

· Latest industry influencing trends and development scenario

· Open up New Markets

· To Seize powerful market opportunities

· Key decision in planning and to further expand market share

· Identify Key Business Segments, Market proposition & Gap Analysis

· Assisting in allocating marketing investments

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies' revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As. Contact Us:

Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 (206) 317 1218 [email protected] Connect with us at https://www.linkedin.com/company/advance-market-analytics https://www.facebook.com/AMA-Research-Media-LLP-344722399585916 https://twitter.com/amareport

0 notes

kenresearch1 · 11 months

Text

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

0 notes

itssashasharma · 3 years

Text

Global Hemato Oncology Testing Market worth $ 4.0 billion by 2024 : Increasing Incidence of Hematologic Cancer

Lab) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp

0 notes

sandlerresearch · 3 years

Text

Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026 published on

https://www.sandlerresearch.org/leukapheresis-market-by-product-devices-filters-columns-disposables-leukopak-mobilized-non-mobilized-indication-all-nhl-multiple-myeloma-application-research-therapeutic-end-user-h.html

“The global leukapheresis products market and the leukopaks market is projected to grow at a CAGR of 8.4% and 41.9% respectively.”

The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

“The leukapheresis disposables segment holds the highest market share, by product, in the leukapheresis products market, in the forecast period.”

On the basis of product, the leukapheresis market is broadly segmented into leukapheresis disposables and leukaphersis devices. Leukapheresis devices are further segmented into centrifugal devices and membrane separators. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.

“The centrifugal devices segment to grow at the highest CAGR in the leukapheresis devices market, in the forecast period.”

Based on type, the leukapheresis devices market is broadly segmented into centrifugal devices and membrane separators. Centrifugal devices segment is expected to grow at the higest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.

“Increasing adoption of leukapheresis products for development of cell-based immunotherapies to promote the growth of this segment in the forecast period.”

Based on application, the leukapheresis products market is segmented into research and therapeutic applications. The research applications segment accounted for the largest share of the leukapheresis products market during the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.

“In the leukapheresis products market by end user segment, blood component providers & blood centers segment holds the highest market share”

On the basis of end user, the leukapheresis products market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.

“In the leukopaks market by type, the diseased leukopaks segment is projected to grow at the highest rate in forecast period”

Based on type, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period”

Based on indication, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia). The acute lymphocytic leukemia segment accounts for the largest share of the leukopaks market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.

“Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period”

Based on indication, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“The pharmaceutical and biotechnology companies segment to grow at the highest CAGR in the leukopaks market, by end user, in the forecast period”

By end user, the leukopaks market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Pharmacuetical and biotechnology companies are projected to grow at the highest CAGR in this market in the forecast period. Thi highest growth rate can be attributed to increasing collaboration of pharmaceutical companies with academic institutes, research centers, and hospitals for new drug development.

“North America holds the largest share in the leukaphereis and leukopaks market, by region, in the forecast period”

The leukapheresis and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The large share of this region can be attributed to the increasing adoption of leukapheresis products for the development of leukoreduced plasma and leukoreduced RBCs, growing adoption of leukopaks as a source of primary cells for research applications, increasing number of clinical trials for the development of CAR T-cell therapy using leukopaks.

A breakdown of the primary participants for the leukapheresis market referred to for this report is provided below:

By Company Type: Tier 1–30%, Tier 2–25%, and Tier 3–45%

By Designation: C-level–40%, Director Level–35%, and Others–25%

By Region: North America–36%, Europe–26%, Asia Pacific–21%, Rest of the World – 17%

A breakdown of the primary participants for the leukopaks market referred to for this report is provided below:

By Company Type: Tier 1–40%, Tier 2–38%, and Tier 3–22%

By Designation: C-level–40%, Director Level–35%, and Others–25%

By Region: North America–39%, Europe–28%, Asia Pacific–22%, Rest of the World – 11%

The prominent players in the global leukapheresis and leukopaks market are Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).

Research Coverage:

The report analyzes the market for various leukapheresis and leukopaks product and their adoption pattern. It aims at estimating the market size and future growth potential of the global leukapheresis and leukopaks market and different segments such as product, application, indication, end user and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global leukapheresis products and leukopaks market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global leukapheresis products and leukopaks market

Market Development: Comprehensive information on the lucrative emerging regions by products, end user, and region

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global leukapheresis products and leukopaks market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global leukapheresis products and leukopaks market.

#Medical Device

0 notes

techsciresearch · 3 years

Text

Plasma Protein Therapeutics Market to Grow with Increasing Targeted Diseases During the Forecast Period | TechSci Research

Rapidly advancing medicinal projects are driving the growth in the global plasma protein therapeutics market in the forecast period.

According to TechSci Research report, “Global Plasma Protein Therapeutics Market By Product (Immunoglobulin, Albumin, Plasma Derived Clotting Factor, Fibrinogen, Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura (ITP), Others), By End User (Hospitals, Research Laboratories and Institutions, Stand-Alone Blood Banks, Others), By Region, Competition Forecast & Opportunities, 2026”, the global plasma protein therapeutics market is anticipated to grow with an impressive CAGR in the forecast period, 2022-2026, on the account of increased demand of effective and efficient treatment therapeutics for the chronic diseases. Moreover, the demand for the treatment is fulfilled by the research and development carried out for the technologically advanced medicine, as well as advanced administrating devices that are influencing the growth of the market in the future five years. Government support to the research and development institutes, along with the favorable investment policies are driving the growth of the market in the future five years. Also, geriatric population is more susceptible to the cardiovascular as well as neurological diseases. Plasma protein therapeutics are widely used for the treatment of these diseases, thus increasing geriatric population is enhancing the chances of the market growth in the future.

Plasma protein therapeutics include biologic medicinal procedures that are used to treat a range of rare, life threatening, chronic and genetic diseases. These therapies are of various types like immunoglobulin therapy, albumin therapy, plasma derived clotting factor, fibrinogen, etc. All these therapies involve the extraction and separation of the required biomolecule from the blood plasma that is recovered from the already infected and cured patient. These biomolecules are efficiently responsible for the treatment of the respective chronic, targeted, and other threatening disorders.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Plasma Protein Therapeutics Market"

https://www.techsciresearch.com/report/plasma-protein-therapeutics-market/7431.html

The global plasma protein therapeutics market is segmented by product, application, end user, competitional landscapes, and regional distribution. Based on application, the market is further bifurcated into hemophilia, primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura (ITP), and others. Hemophilia is an inherited genetic disorder, that renders the human body’s ability to make blood clots and therefore is unable to stop bleedings in case of incision wounds, or any tearing and rupture of epidermal cells. Primary immunodeficiency disorder (PID) is anticipated to hold the largest shares of the market in the forecast years. The market segment is anticipated to dominate the market on the backbone of increased expansion of clinical application for immunoglobulins, approval of SCIGs, and high treatment costs. Primary immunodeficiency diseases include more than 200 rare, chronic diseases that result from a defect in the immune system. The surge in demand is due to these chronic diseases.

Companies holding major shares of the global plasma protein therapeutics market include CSL Behring LLC, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, Kedrion S.P.A., China Biologics Products Holdings, Inc., Takeda Pharmaceutical Company Ltd., Baxter International Ltd., Bio Products Laboratory Ltd., ADMA Biologics, Inc., Pfizer Inc., Ferring BV, HEMA Biologics LLC, among others.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7431

Customers can also request for 10% free customization on this report.

“North America is the maximum potential market for the next five years with patient pool, availability of well-developed infrastructure for storing, and maintaining high-quality source plasma. Moreover, the healthcare industry in the region is of excellent quality and thereby the region is leading in terms of largest market for plasma protein therapeutics. Also, the FDA approvals, and research and development of the technologically advanced drugs is being carried out in the same region. Europe region is also expected to hold the significant share of the market owing to the number of market giants available in the region. Asia Pacific is anticipated to be of some significance owing to various research and developments being carried out. Moreover, the economies like China and India provide cheaper medical services thus, medical tourism might influence the market growth in the Asia Pacific region,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Plasma Protein Therapeutics Market, By Product (Immunoglobulin, Albumin, Plasma Derived Clotting Factor, Fibrinogen, Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura (ITP), Others), By End User (Hospitals, Research Laboratories and Institutions, Stand-Alone Blood Banks, Others), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global plasma protein therapeutics and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the global plasma protein therapeutics market.

Browse Related Reports:

Global Gastric Cancer Therapeutics Market, By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor, Gastric Neuroendocrine Tumors), By Molecule Type (Small Molecule, Biologics), By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy) By Mode of Action (Programmed Cell Death Protein 1 Inhibitors, Human Epidermal Growth Factor Receptor Antagonists, Vascular Endothelial Growth Factor Receptor Antagonists, Others), By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/gastric-cancer-therapeutics-market/7403.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #market research reports #Global Plasma Protein Therapeutics Market #Plasma Protein Therapeutics Market #Plasma Protein Therapeutics Market Size #Plasma Protein Therapeutics Market Forecast #Healthcare

0 notes

leonfrancisblog · 4 years

Text

Hemato Oncology Testing Market Global Trends, Growth, Opportunities, Market Size Forecast to 2027|Major Competitors Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc

Hemato oncology testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hemato oncology testing market This hemato oncology testing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief our team will help you create a revenue impact solution to achieve your desired goal.

Increasing cases of hematologic cancer and growing awareness about the advanced treatment therapies among population will drive the market growth. Rising cases of myeloma cancers and lymphoma will also affect the market positively. Leukemia patients are constantly keeping track on the status of minimal residual disease which is also expected to affect the market positively. Favourable reimbursement policy on the hemato oncology testing products will also enhance the market growth. On the other hand, rising collaboration between manufacturer, increasing conferences on personalized medicines, and growing demand for advanced treatment options will also create new opportunities for the hemato oncology testing market in the forecast period of 2020- 2027.

Global Hemato Oncology Testing Market By Product & Services (Services, Assay Kits), Cancer Type (Leukemia, Lymphoma, Other Cancers), Technology (PCR, IHS, NGS, Cytogenetics, Other), End- Users (Clinical Laboratories, Hospitals, Academic & Research Institutes, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Share Forecast to 2027Hemato Oncology Testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growat a CAGR of 14.10% in the above-mentioned forecast period. Increasing cases of leukemia and increasing demand for personalized medicines will create new opportunities for this market in the forecast period of 2020- 2027.Hemotology is that route of medicine which deals with the treatment, causes, and other problems associated with the blood. On the other hand, oncology is connected with the study of the treatment, diagnosis, and other problem associated with cancer. Hematolo-oncology is the method used to treat diseases and blood disorders and cancers.

Get An Sample Request on Get an Sample Request on Global Hemato Oncology Testing Market: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hemato-oncology-testing-market

Hemato Oncology Testing Market Country Level Analysis:

Hemato oncology testing market is analyzed and market size insights and trends are provided product & services, cancer type, technology and end use as referenced above.

The country section of the hemato oncology testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. The countries covered in the hemato oncology testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America. North America dominates the hemato oncology testing market due to favourable reimbursement policy for hemato oncology testing products while Asia-Pacific is expected to grow at the highest growth rate in the forecast period 2020 to 2027 due to increasing patient population.

Healthcare Infrastructure growth Installed base and New Technology Penetration:

Hemato oncology testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for hemato oncology testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hemato oncology testing market. The data is available for historic period 2010 to 2018.

Global Hemato Oncology Testing Market Scope and Market Size:

Hemato oncology testing market is segmented of the basis of product & services, cancer type, technology and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product & services, hemato oncology testing market is segmented into services, and assay kits.

On the basis of cancer type, the hemato oncology testing market is classified into leukemia, lymphoma, and other cancers. Leukemia is further divided into acute myeloid leukemia, acute lymphocytic leukemia, and other leukemia. Lymphoma is segmented into non-Hodgkin lymphoma and Hodgkin lymphoma. The hemato oncology testing market is also segmented on the basis of technology as PCR, IHS, NGS, cytogenetic, and other. The global hemato oncology testing market has also been segmented based on the end use into clinical laboratories, hospitals, academic & research institutes, and others.

The major players covered in the hemato oncology testing market report are F. Hoffmann-La Roche Ltd, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc., ARUP Laboratories., Invivoscribe, Inc., CORE Diagnostics, Genoptix, Inc., GenPath, NeoGenomics Laboratories, Inc., Siemens AG, among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Table of Content https://www.databridgemarketresearch.com/toc/?dbmr=global-hemato-oncology-testing-market

Reasons for buying this Global Hemato Oncology Testing Market:

Laser Capture Global Hemato Oncology Testing Market aids in understanding the crucial product segments and their perspective.

Initial graphics and exemplified that a SWOT evaluation of large sections supplied from the Laser Capture Global Hemato Oncology Testing Market.

Even the Laser Capture Global Hemato Oncology Testing Market economy provides pin line evaluation of changing competition dynamics and retains you facing opponents.

This report provides a more rapid standpoint on various driving facets or controlling Medical Robotic System promote advantage.

This worldwide Locomotive report provides a pinpoint test for shifting dynamics that are competitive.

The key questions answered in this report:

What will be the Market Size and Growth Rate in the forecast year?

What is the Key Factors driving Laser Global Hemato Oncology Testing Market?

What are the Risks and Challenges in front of the market?

Who are the Key Vendors in Global Hemato Oncology Testing Market?

What are the Trending Factors influencing the market shares?

What is the Key Outcomes of Porter’s five forces model

Access Full Report https://www.databridgemarketresearch.com/reports/global-hemato-oncology-testing-market

Browse Related Report:

North America Metabolic Testing Market

Pharmaceutical Equipment Testing Market

Sterility Testing Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Market by Type Market Development Market Forecast Market Size Future Innovation Market Future Trends Market Share Market Demand Market Growt

0 notes

udaycmi · 4 years

Link

The global platelet aggregation devices market size is expected to reach USD 1,556.8 million by 2027 according to a new study by Polaris Market Research. The report “Platelet Aggregation Devices Market Share, Size, Trends, Industry Analysis Report, By Product (Systems, Reagents, Consumables and Accessories); By Application (Research Applications, Clinical Applications, Others); By End Use (Standalone Hospitals, Diagnostic Laboratories, Research and Academic Institutes, Blood Banks, and Other End Users); By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Get Sample Copy of report: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Polaris Market Research

Phone: 1-646-568-9980

Email: [email protected]

Web: www.polarismarketresearch.com

0 notes

medicaldevicetech · 4 years

Text

Spirometry Market - Report And Global Demand by 2023

Spirometry Market Overview:

The global spirometry market is expecting to touch a valuation of USD 1,106.46 million by 2023, according to Market Research Future (MRFR). The high prevalence of respiratory disorders is the major factor driving the market growth from 2018 to 2023 (forecast period). Rising cases of chronic obstructive pulmonary disorders (COPD), technological advances in respiratory care devices, and the expanding geriatric population are factors expected to spur market demand till 2023. As per a report by Asthma UK in 2016, nearly 1,410 people died from asthma.

Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/6539

Government initiatives to curtail smoking habits, focus on breathing diseases, rising levels of air pollution, and adoption of spirometers at homes are factors likely to augur market growth. Awareness of reimbursement policies among the public and clinicians are projected to drive patients towards taking these tests. But high costs of spirometers can act as a deterrent against market growth.

Spirometry Market Segmentation:

The spirometry market forecast can be segmented by product, technology, application, and end-user.

By product, the market is segmented into table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. The table-top spirometry segment accounted for 49.9% market share in 2017, followed by hand-held (31%), and desktop (19.1%). This can be attributed to adoption of spirometers in hospitals and clinics. But the desktop segment is touted to register the highest CAGR of 10.58% during the forecast period owing to its rapid diagnosis rate and increasing use of computer-based applications.

By technology, the market covers flow measurement spirometry, volume spirometry, and peak flow meters (PFM). The flow measurement spirometry segment accounted for 50.3% share in 2017. This can be attributed to its lightweight nature and compact size. Its functionality based on the familiar table-top spirometer technology and lack of frequent calibration make it popular among clinicians. But the PFM technology can register 10.58% CAGR over the forecast period to reach USD 149.76 million by 2023.

Major applications of the spirometry market include diagnostic and treatment monitoring. The diagnostic segment is further sub-segmented into asthma, interstitial pulmonary fibrosis, and COPD. The diagnostic segment accounted for 68.93% share of the market in 2017, spurred by the prevalence of breathing diseases such as asthma. But the treatment monitoring segment can exhibit the highest CAGR during the review period to reach a valuation of USD 353 million by 2023. Its valuation in 2018 was suggested to be USD 214.12 million.

Key market end-users include hospitals & clinics, research & academic institutes, diagnostic centers, and home care. The home care segment is projected to enjoy a 9.90% CAGR to reach a valuation of USD 71.14 million by 2023 from USD 44.38 million in 2018.

Spirometry Market Regional Analysis:

The spirometry market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas accounted for 39.74% share in the global market in 2017, followed by Europe and APAC. This can be attributed to economies such as the U.S. which are the earliest adopters of latest technologies coupled with the large patient pool suffering from respiratory disorders. The region is likely to enjoy a 10.25% CAGR over the forecast period.

The Europe spirometry market is expected to enjoy a CAGR similar to the Americas market over the forecast period to touch a valuation of USD 322.33 million by 2023. This can be credited to rising number of asthma cases and ballooned healthcare expenditure of nations such as Germany and France.

The MEA region can experience a respectable CAGR during the review period owing to improvements of healthcare infrastructure and enhanced healthcare budgets of Kuwait, Qatar, and Dubai.

The APAC region is expected to exhibit a 10.94% CAGR over the forecast period owing to high cases of chronic diseases, awareness of respiratory devices, and increased healthcare budgets of developed nations in the region. The growing geriatric populace in China and Japan can contribute to regional market revenue till 2023.

Spirometry Market Competitive Dashboard:

Key players in the spirometry market include Smiths Medical Inc. (U.S.), Vitalograph (U.K.), MGC Diagnostics Corporation (U.S.), Hill-Rom Holdings, Inc. (U.S.), Schiller AG (Switzerland), COSMED srl (Italy), Midmark Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Carefusion Corporation (U.S.), Nihon Kohden Corporation (Germany), and Koninklijke Philips N.V. (The Netherlands).

Access Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539

Covid19 Impact on Healthcare Industry Report

Gastroscopes Market research Report - Global Forecast till 2023: https://www.marketresearchfuture.com/reports/acute-myeloid-leukemia-treatment-market-3223

Advanced Baby Monitors Market research Report - Global Forecast till 2025: https://www.marketresearchfuture.com/reports/advanced-baby-monitors-market-6525

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: [email protected]

#Spirometry Market

0 notes

myabhijitr · 5 years

Text

Biologics Market Industry Growth, Size, Share, Outlook, and Forecast, 2018 to 2026

Biologics market size is expected to boost owing to the increasing product pipeline from different companies like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and 11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

Furthermore, the biologics market revenue is growing because of increasing number of Food and Drug Administration (FDA) approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017 US FDA approved 46 biologics and in December 2017, GlaxoSmithKline’s biologic Nucala was approved for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).

Key players operating in the global biologics market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.

Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2663

Important Features that are under offering & key highlights of the report :

1) Can we add or profiled new company as per our need? Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by research team depending upon the difficulty of survey.

** Data availability will be confirmed by research in case of privately held company. Upto 3 players can be added at no added cost.

2) What all regional segmentation covered? Can specific country of interest be added? Currently, research report gives special attention and focus on following regions: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)

** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

3) Can inclusion of additional Segmentation / Market breakdown is possible? Yes, inclusion of additional segmentation / Market breakdown is possible subject to data availability and difficulty of survey. However a detailed requirement needs to be shared with our research before giving final confirmation to client.

Receive Sample on Biologics Research: https://www.coherentmarketinsights.com/insight/request-sample/2663

Competitive Analysis:

The research report on Biologics Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2026. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities. The report classifies the market into different segments based on technique, application and end-user. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2663

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#biologics market #biologics market industry #biologics market growth

0 notes